MSD’s acquisition of Terns Pharmaceuticals is a calculated, forward-looking manoeuvre to secure the next generation of ...
Use of multiplex mutation genotyping to identify novel and protective mutations in breast cancer Expression of BCR-ABL1 in hematopoietic stem cells can alone induce a chronic myeloid leukemia (CML) ...
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial ...
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study ...
Enliven Therapeutics' ELVN-001 shows promising interim data, achieving a 44% major molecular response rate in heavily pre-treated CML patients within 12 weeks. ELVN-001 targets the BCR-ABL gene fusion ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: ...
Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation ...
Chronic myeloid leukemia may seem to appear suddenly, but new research shows it begins years before diagnosis with an explosive surge of growth. Scientists tracked how a single genetic accident—the ...
Leukemia is an umbrella term for multiple different cancers that form in the blood, one such member of the leukemia family being chronic myelogenous leukemia (CML). CML is caused by a chromosomal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results